Search

Your search keyword '"Dutz, Jan"' showing total 688 results
Start Over Author "Dutz, Jan"
688 results on '"Dutz, Jan"'

1. Rosai-Dorfman-Destombes disease in adults: a single center experience

Author

Leung, Emily, Pryma, Collin, Murphy, Stephen, Harrison, Rebecca, Peterson, Erica, Tsang, Peter W. K., Varghese, Julia, You, Xiaotian (Julie), Slack, Graham W., Skinnider, Brian F., Ng, Tony, Young, Sean, Burrell, Steven, Stubbins, Ryan, Lim, Howard, Carruthers, Mollie, Dutz, Jan, Diamond, Eli L., and Chen, Luke Y. C.

Published
2024
Full Text
View/download PDF

4. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis

Author

Greenbaum, Carla, Krisher, Jeffrey, Skyler, Jay, Wherrett, Diane, Hannelius, Ulf, Lindqvist, Anton, Nowak, Christoph, Bebu, Ionut, Braffett, Barbara, Napolitano, Antonella, Jan Mohamed, Salim, Weir, Gordon, Nepom, Gerald, Beck, Roy, Richard, Claudia, Hedrick, Joseph, Ludvigsson, Johnny, Von Herrath, Matthias, Leon, Francisco, Ramos, Eleanor, Narendran, Parth, Gitelman, Stephen, Dabelea, Dana, Andrews, Rob, Haller, Michael, Jensen, Elizabeth, Harold, Kevan, Dutz, Jan, Taylor, Peter N, Collins, Kimberly S, Lam, Anna, Karpen, Stephen R, Greeno, Brianna, Walker, Frank, Lozano, Alejandro, Atabakhsh, Elnaz, Ahmed, Simi T, Marinac, Marjana, Latres, Esther, Senior, Peter A, Rigby, Mark, Gottlieb, Peter A, and Dayan, Colin M

Published
2023
Full Text
View/download PDF

6. Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel

Author

Papp, Kim A., Melosky, Barbara, Sehdev, Sandeep, Hotte, Sebastien J., Beecker, Jennifer R., Kirchhof, Mark G., Turchin, Irina, Dutz, Jan P., Gooderham, Melinda J., Gniadecki, Robert, Hong, Chih-ho, Lambert, Jo, Lynde, Charles W., Prajapati, Vimal H., and Vender, Ronald B.

Published
2023
Full Text
View/download PDF

12. Residual Disease Activity In Canadian Patients With Psoriatic Arthritis (PsA) Treated With Advanced Therapies: Results From A Multi-Registry Analysis (UNISON-PsA)

Author

Gladman, Dafna D., primary, Chandran, Vinod, additional, Rosen, Cheryl F., additional, Rohekar, Sherry, additional, Boyd, Tristan, additional, Eder, Lihi, additional, Rahman, Proton, additional, Dutz, Jan, additional, Chan, Jonathan, additional, Haydey, Richard P., additional, Barac, Snezana, additional, Laliberté, Marie-Claude, additional, Girard, Tanya, additional, Fournier, Pierre-André, additional, Sutton, Mitchell, additional, Pereira, Daniel, additional, Chim, Tina, additional, Coupal, Louis, additional, and Choquette, Denis, additional

Published
2024
Full Text
View/download PDF

15. Residual Disease Activity in Canadian Patients With Psoriatic Arthritis Treated With Advanced Therapies: Results From a Multiregistry Analysis (UNISON-PsA).

Author

Gladman, Dafna D., Chandran, Vinod, Rosen, Cheryl F., Rohekar, Sherry, Boyd, Tristan, Eder, Lihi, Rahman, Proton, Dutz, Jan, Chan, Jonathan, Haydey, Richard P., Barac, Snezana, Laliberté, Marie-Claude, Girard, Tanya, Fournier, Pierre-André, Sutton, Mitchell, Pereira, Daniel, Chim, Tina, Coupal, Louis, and Choquette, Denis

Published
2024
Full Text
View/download PDF

16. Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients.

Author

Beckett, Madelaine, Tan, Julia, Bonnardeaux, Evelyne, Dutz, Jan, Shojania, Kamran, To, Fergus, Obrzut, Anthony, Aviña-Zubieta, J, and Huang, Kun

Subjects
DERMATOMYOSITIS, MYOSITIS, PATIENT safety, IMMUNOSUPPRESSIVE agents, DEATH, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, JANUS kinases, LONGITUDINAL method, MUSCLE strength, DRUG efficacy, METROPOLITAN areas, MEDICAL records, ACQUISITION of data, NEUROTRANSMITTER uptake inhibitors, PHENOTYPES, EVALUATION
Abstract

Objectives To evaluate the efficacy and safety of tofacitinib in treatment-refractory inflammatory myositis in a real-world clinical setting. Methods All patients with refractory inflammatory myositis treated with tofacitinib from a single urban centre in Vancouver, British Columbia, Canada, were included from June 2016 to December 2022. The medical records of these patients were retrospectively reviewed. Results A total of 41 patients were included, 23 with classic DM, 12 with amyopathic DM (ADM) and six with PM phenotype. The patients failed an average of four to five non-steroidal immunosuppressants before initiation of tofacitinib. In the classic DM and ADM group, tofacitinib offered clinically and statistically significant cutaneous improvement. In all myositis patients including the PM phenotype, no meaningful muscle strength response to tofacitinib was observed. 53.7% of the patients discontinued tofacitinib due to lack of benefit or death. Of the 19 patients who remained on tofacitinib at the conclusion of this study, tofacitinib demonstrated clinically and statistically significant improvement in cutaneous disease activity. Conclusion Tofacitinib appears to be highly effective in targeting cutaneous manifestations in classic DM and ADM; however, minimal benefit in muscle strength in the DM or PM phenotype were observed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Identification of Autoantigen Epitopes in Alopecia Areata.

Author

Wang, Eddy HC, Yu, Mei, Breitkopf, Trisia, Akhoundsadegh, Noushin, Wang, Xiaojie, Shi, Feng-Tao, Leung, Gigi, Dutz, Jan P, Shapiro, Jerry, and McElwee, Kevin J

Subjects
Leukocytes, Mononuclear, Keratinocytes, Melanocytes, Humans, Alopecia Areata, Intermediate Filament Proteins, HLA-A2 Antigen, Autoantigens, Epitopes, Cytokines, Culture Media, Conditioned, Enzyme-Linked Immunosorbent Assay, Prognosis, Apoptosis, Haplotypes, Algorithms, Adult, Aged, Middle Aged, Female, Male, Interferon-gamma, Young Adult, Autoimmune Disease, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Clinical Sciences, Oncology and Carcinogenesis, Dermatology & Venereal Diseases
Abstract

Alopecia areata (AA) is believed to be a cell-mediated autoimmune hair loss disease. Both CD4 and cytotoxic CD8 T cells (CTLs) are important for the onset and progression of AA. Hair follicle (HF) keratinocyte and/or melanocyte antigen epitopes are suspected potential targets of autoreactive CTLs, but the specific epitopes have not yet been identified. We investigated the potential for a panel of known epitopes, expressed by HF keratinocytes and melanocytes, to induce activation of CTL populations in peripheral blood mononuclear cells. Specific synthetic epitopes derived from HF antigens trichohyalin and tyrosinase-related protein-2 induced significantly higher frequencies of response in AA CTLs compared with healthy controls (IFN-gamma secretion). Apoptosis assays revealed conditioned media from AA peripheral blood mononuclear cells stimulated with trichohyalin peptides elevated the expression of apoptosis markers in primary HF keratinocytes. A cytokine array revealed higher expression of IL-13 and chemokine ligand 5 (CCL5, RANTES) from AA peripheral blood mononuclear cells stimulated with trichohyalin peptides compared with controls. The data indicate that AA affected subjects present with an increased frequency of CTLs responsive to epitopes originating from keratinocytes and melanocytes; the activated CTLs secreted soluble factors that induced apoptosis in HF keratinocytes. Potentially, CTL response to self-antigen epitopes, particularly trichohyalin epitopes, could be a prognostic marker for human AA.

Published
2016

19. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis

Author

Taylor, Peter N, primary, Collins, Kimberly S, additional, Lam, Anna, additional, Karpen, Stephen R, additional, Greeno, Brianna, additional, Walker, Frank, additional, Lozano, Alejandro, additional, Atabakhsh, Elnaz, additional, Ahmed, Simi T, additional, Marinac, Marjana, additional, Latres, Esther, additional, Senior, Peter A, additional, Rigby, Mark, additional, Gottlieb, Peter A, additional, Dayan, Colin M, additional, Greenbaum, Carla, additional, Krisher, Jeffrey, additional, Skyler, Jay, additional, Wherrett, Diane, additional, Hannelius, Ulf, additional, Lindqvist, Anton, additional, Nowak, Christoph, additional, Bebu, Ionut, additional, Braffett, Barbara, additional, Napolitano, Antonella, additional, Jan Mohamed, Salim, additional, Weir, Gordon, additional, Nepom, Gerald, additional, Beck, Roy, additional, Richard, Claudia, additional, Hedrick, Joseph, additional, Ludvigsson, Johnny, additional, Von Herrath, Matthias, additional, Leon, Francisco, additional, Ramos, Eleanor, additional, Narendran, Parth, additional, Gitelman, Stephen, additional, Dabelea, Dana, additional, Andrews, Rob, additional, Haller, Michael, additional, Jensen, Elizabeth, additional, Harold, Kevan, additional, and Dutz, Jan, additional

Published
2023
Full Text
View/download PDF

28. List of Contributors

Author

Akkoç, Nurullah, primary, Boonen, Annelies, additional, Brown, Matthew A., additional, Caballero-Uribe, Carlo V., additional, Carron, Philippe, additional, Ciccia, Francesco, additional, Deodhar, Atul, additional, Dutz, Jan Peter, additional, Haroon, Nigil, additional, Khan, Muhammad Asim, additional, Kiltz, Uta, additional, Kiwalkar, Sonam, additional, Lambert, Robert George William, additional, Lories, Rik, additional, Magrey, Marina N., additional, Maksymowych, Walter P., additional, Mease, Philip, additional, Navarro-Compán, Victoria, additional, Özgöçmen, Salih, additional, Poddubnyy, Denis, additional, Proft, Fabian, additional, Reveille, John D., additional, Rosenbaum, James T., additional, Schwartzman, Sergio, additional, Sieper, Joachim, additional, Srinath, Archita, additional, Sternes, Peter R., additional, Van den Bosch, Filip, additional, Ward, Michael M., additional, Webers, Casper, additional, Xu, Huji, additional, and Zeng, Fanxing, additional

Published
2019
Full Text
View/download PDF

29. Extraarticular Manifestations

Author

Kiwalkar, Sonam, primary, Rosenbaum, James T., additional, Schwartzman, Sergio, additional, Dutz, Jan Peter, additional, and Van den Bosch, Filip, additional

Published
2019
Full Text
View/download PDF

35. Table S2 - Supplemental material for Chilblain-Like Lesions (CLL) Coinciding With the SARS-CoV-2 Pandemic in Children: A Systematic Review

Author

Starkey, Samantha Y., Kashetsky, Nadia, Lam, Joseph M., Dutz, Jan, and Mukovozov, Ilya M.

Subjects
Medicine
Abstract

Supplemental material, Table S2, for Chilblain-Like Lesions (CLL) Coinciding With the SARS-CoV-2 Pandemic in Children: A Systematic Review by Samantha Y. Starkey, Nadia Kashetsky, Joseph M. Lam, Jan Dutz and Ilya M. Mukovozov in Journal of Cutaneous Medicine and Surgery

Published
2023
Full Text
View/download PDF

36. Table S1 - Supplemental material for Top Ten Research Priorities for Psoriasis, Atopic Dermatitis and Hidradenitis Suppurativa: The SkIN Canada Priority Setting Initiative

Author

Drucker, Aaron M., Kleiner, Omer, Manion, Rachael, Philip, Anie, Dutz, Jan, Barnard, Kathleen, Fradette, Julie, Germain, Lucie, Gniadecki, Robert, Litvinov, Ivan, Logsetty, Sarvesh, Manolson, Morris, Mydlarski, P. Régine, Piguet, Vincent, Ward, Debbie, Zhou, Youwen, and Chan, An-Wen

Subjects
Medicine
Abstract

Supplemental material, Table S1, for Top Ten Research Priorities for Psoriasis, Atopic Dermatitis and Hidradenitis Suppurativa: The SkIN Canada Priority Setting Initiative by Aaron M. Drucker, Omer Kleiner, Rachael Manion, Anie Philip, Jan Dutz, Kathleen Barnard, Julie Fradette, Lucie Germain, Robert Gniadecki, Ivan Litvinov, Sarvesh Logsetty, Morris Manolson, P. Régine Mydlarski, Vincent Piguet, Debbie Ward, Youwen Zhou and An-Wen Chan in Journal of Cutaneous Medicine and Surgery

Published
2023
Full Text
View/download PDF

37. Figure S1 - Supplemental material for Chilblain-Like Lesions (CLL) Coinciding With the SARS-CoV-2 Pandemic in Children: A Systematic Review

Author

Starkey, Samantha Y., Kashetsky, Nadia, Lam, Joseph M., Dutz, Jan, and Mukovozov, Ilya M.

Subjects
Medicine
Abstract

Supplemental material, Figure S1, for Chilblain-Like Lesions (CLL) Coinciding With the SARS-CoV-2 Pandemic in Children: A Systematic Review by Samantha Y. Starkey, Nadia Kashetsky, Joseph M. Lam, Jan Dutz and Ilya M. Mukovozov in Journal of Cutaneous Medicine and Surgery

Published
2023
Full Text
View/download PDF

43. Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

Author

Sunderkötter, Cord H., Zelger, Bernhard, Chen, Ko‐Ron, Requena, Luis, Piette, Warren, Carlson, J. Andrew, Dutz, Jan, Lamprecht, Peter, Mahr, Alfred, Aberer, Elisabeth, Werth, Victoria P., Wetter, David A., Kawana, Seiji, Luqmani, Raashid, Frances, Camille, Jorizzo, Joseph, Watts, J. Richard, Metze, Dieter, Caproni, Marzia, Alpsoy, Erkan, Callen, Jeffrey P., Fiorentino, David, Merkel, Peter A., Falk, Ronald J., and Jennette, J. Charles

Published
2018
Full Text
View/download PDF

44. Proceeding report of the Symposium on Hidradenitis Suppurativa Advances (SHSA)

Author

Mehdizadeh, Ali, Alavi, Afsaneh, Alhusayen, Raed, Bauer, Boris, Bechara, Falk G., Bourcier, Marc, Brassard, Alain, Djamei, Vahid, Dutz, Jan, George, Ralph, Ghias, Mondana, Gooderham, Melinda, Hamzavi, Iltefat, Hoffman, Lauren K., Hou, Angela, Hu, Howard, Kimball, Alexa B., Kirchhof, Mark, Kryzskaya, Darya, Liy Wong, Maria del Carmen, Lowes, Michelle A., Lynde, Charles W., McLellen, Chelsea, Prens, Errol, Prens, lisette, Rogalska, Tetyana, Sibbald, Ronald Gary, Sisic, Mia, Tan, Marcus G., and Wong, Dennis D.

Published
2018
Full Text
View/download PDF

46. Scleroderma

Author

Orteu, Catherine H., Dutz, Jan P., Hunzelmann, Nicolas, Krieg, Thomas, and Hertl, Michael, editor

Published
2001
Full Text
View/download PDF

47. Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity:52-Week Post Hoc Results from SPIRIT-H2H

Author

Kristensen, Lars Erik, Okada, Masato, Tillett, William, Leage, Soyi Liu, El Baou, Celine, Sapin, Christophe, Bradley, Andrew J., Meszaros, Gabriella, Dutz, Jan P., de Vlam, Kurt, Kristensen, Lars Erik, Okada, Masato, Tillett, William, Leage, Soyi Liu, El Baou, Celine, Sapin, Christophe, Bradley, Andrew J., Meszaros, Gabriella, Dutz, Jan P., and de Vlam, Kurt

Abstract

Introduction: Ixekizumab, a selective interleukin-17A antagonist, was compared with adalimumab in the SPIRIT-H2H study (NCT03151551) in patients with psoriatic arthritis (PsA) and concomitant psoriasis. This post hoc analysis reports outcomes to week 52 in patients from SPIRIT-H2H, stratified by baseline psoriasis severity. Methods: SPIRIT-H2H was a 52-week, multicenter, randomized, open-label, rater-blinded, parallel-group study of biologic disease-modifying antirheumatic drug (DMARD)-naïve patients (N = 566) with PsA and active psoriasis (≥ 3% body surface area involvement). Patients were randomized to ixekizumab or adalimumab (1:1) with stratification by baseline concomitant use of conventional synthetic DMARDs and psoriasis severity (with/without moderate-to-severe psoriasis). Patients received on-label dosing according to psoriasis severity. The primary endpoint was the proportion of patients simultaneously achieving ≥ 50% improvement in American College of Rheumatology criteria (ACR50) and 100% improvement in Psoriasis Area Severity Index (PASI100) at week 24. Secondary endpoints included musculoskeletal, disease activity (defined by composite indices), skin and nail, quality of life and safety outcomes. In this post hoc analysis, primary and secondary endpoints of SPIRIT-H2H were analyzed by baseline psoriasis severity. Results: A greater proportion of patients achieved the combined endpoint of ACR50 + PASI100 and PASI100 with ixekizumab compared with adalimumab at weeks 24 and 52, regardless of baseline psoriasis severity. ACR response rates were similar for ixekizumab and adalimumab across both patient subgroups. For musculoskeletal outcomes, similar efficacy was seen for ixekizumab and adalimumab, but ixekizumab showed greater responses for skin outcomes regardless of psoriasis severity. The safety profiles of ixekizumab and adalimumab were consistent between subgroups. Conclusions: Regardless of baseline psoriasis severity, ixekizumab demonstrated grea

Published
2022

48. Top Ten Research Priorities for Psoriasis, Atopic Dermatitis and Hidradenitis Suppurativa: The SkIN Canada Priority Setting Initiative.

Author

Drucker, Aaron M., Kleiner, Omer, Manion, Rachael, Philip, Anie, Dutz, Jan, Barnard, Kathleen, Fradette, Julie, Germain, Lucie, Gniadecki, Robert, Litvinov, Ivan, Logsetty, Sarvesh, Manolson, Morris, Mydlarski, P. Régine, Piguet, Vincent, Ward, Debbie, Zhou, Youwen, Chan, An-Wen, Abbas, Mariam, Alhusayen, Raed, and Cenedese, Lisa

Abstract

Background: The Skin Investigation Network of Canada (SkIN Canada) is a new national skin research network. To shape the research landscape and ensure its value to patient care, research priorities that are important to patients, caregivers, and health care providers must be identified. Objectives: To identify the Top Ten research priorities for 9 key skin conditions. Methods: We first surveyed health care providers and researchers to select the top skin conditions for future research within the categories of inflammatory skin disease, skin cancers (other than melanoma), and wound healing. For those selected skin conditions, we conducted scoping reviews to identify previous priority setting exercises. We combined the results of those scoping reviews with a survey of patients, health care providers, and researchers to generate lists of knowledge gaps for each condition. We then surveyed patients and health care providers to create preliminary rankings to prioritize those knowledge gaps. Finally, we conducted workshops of patients and health care providers to create the final Top Ten lists of research priorities for each condition. Results: Overall, 538 patients, health care providers, and researchers participated in at least one survey or workshop. Psoriasis, atopic dermatitis and hidradenitis suppurativa (inflammatory skin disease); chronic wounds, burns and scars (wound healing); and basal cell, squamous cell and Merkel cell carcinoma (skin cancer) were selected as priority skin conditions. Top Ten lists of knowledge gaps for inflammatory skin conditions encompassed a range of issues relevant to patient care, including questions on pathogenesis, prevention, non-pharmacologic and pharmacologic management. Conclusions: Research priorities derived from patients and health care providers should be used to guide multidisciplinary research networks, funders, and policymakers in Canada and internationally. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results